Donor CMV serostatus not predictive of relapse in D-/R- pediatric HCT.
Travi
Giovanna
G
Pergam
Steven A
SA
Xie
Hu
H
Boeckh
Michael J
MJ
D000212:Acyclovir / Q000008:administration & dosage / Q000627:therapeutic use; D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood; D000956:Antigens, Viral / Q000097:blood; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003587:Cytomegalovirus / Q000276:immunology / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000517:prevention & control / Q000635:transmission; D018572:Disease-Free Survival; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage / Q000627:therapeutic use; D015774:Ganciclovir / Q000008:administration & dosage / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects; D011183:Postoperative Complications / Q000453:epidemiology*; D011292:Premedication; D016016:Proportional Hazards Models; D012008:Recurrence; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects; D014184:Transplantation, Homologous / Q000009:adverse effects; D014775:Virus Activation; D055815:Young Adult
D000914:Antibodies, Viral; D000956:Antigens, Viral; D000998:Antiviral Agents; D019653:Myeloablative Agonists; D017245:Foscarnet; D015774:Ganciclovir; D000212:Acyclovir